Galapagos reports Q1 EPS (EUR 2.30) vs. EUR 1.40 last year

Reports Q1 revenue EUR 75M vs. EUR 62.4M last year. “We are making progress toward the planned separation announced early this year, positioning Galapagos (GLPG) to be a leader in cell therapy, focused on addressing the high unmet needs of patients with hematologic malignancies with our potential best-in-class cell therapies,” said Paul Stoffels1, MD, CEO and chair of the board of directors of Galapagos. “Our unique decentralized manufacturing platform is designed to deliver fresh, stem-like, early memory cells with a vein-to-vein time of seven days, and aims to redefine cell therapy by providing faster and broader access with the potential for improved patient outcomes. In addition to the first U.S. patient now dosed in the ATALANTA-1 study of GLPG5101, we have selected mantle cell lymphoma as the lead registrational indication for the program. GLPG5101 is being advanced toward pivotal development in 2026, with the goal of obtaining the first approval in 2028. This is just the beginning of our broader mission of bringing GLPG5101 to more patients impacted by hematological malignancies across eight indications with high unmet need.”